Ocular Surface Disease: An Unexpected Driver of Adverse Outcomes in Glaucoma (Online CME Monograph)
Activity Description and Purpose
Both glaucoma and ocular surface disease (OSD) increase in prevalence with aging and often coexist. Common therapies for glaucoma may increase the risk for OSD and may aggravate existing OSD, mediated primarily by the ubiquitous preservative benzalkonium chloride. Comorbid OSD can have the undesirable effect of reducing adherence with glaucoma therapy to avoid the symptoms of OSD, which in turn can lead to glaucoma progression and potential visual dysfunction. Successful management requires surveillance for OSD among patients with glaucoma, appropriate workup of suspected OSD in these patients, and understanding of the causal relationship between topical glaucoma medical therapy and OSD in order to optimize outcomes of both conditions. In this educational activity, a panel of glaucoma and ocular surface experts will review the relationship between OSD and glaucoma and the role of OSD on adherence to glaucoma therapy and provide strategies for successful assessment of patients with glaucoma. The desired results of this activity are to improve the outcomes of patients with glaucoma.
This educational activity is intended for ophthalmologists.
After completing this activity, participants will be better able to:
- Describe the relationship between preservatives used in topical glaucoma medications and ocular surface disease
- Discuss the role of preservative-mediated ocular surface disease in nonadherence to topical glaucoma treatment
- Assess patients who use preserved topical glaucoma medication for ocular surface disease
Ike K. Ahmed, MD, FRCSC (Chair)
Fellowship Director, Glaucoma and Anterior Segment Surgery (GAASS) Fellowship
Research Director, Kensington Eye Institute
University of Toronto
Division Head, Ophthalmology
Trillium Health Partners
Christophe Baudouin, MD, PhD, FARVO
Professor of Ophthalmology
Chairman, Department of Ophthalmology
Quinze-Vingts National Ophthalmology Hospital
Research Director, Vision Institute
Preeya K. Gupta, MD
Triangle Eye Consultants
Durham, North Carolina
Nathan M. Radcliffe, MD
Associate Clinical Professor of Ophthalmology
Mount Sinai Hospital
New York Eye and Ear Infirmary of Mount Sinai
New York, New York
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity.
Ike K. Ahmed, MD, FRCSC, is a consultant for Aequus BioPharma, Inc, Aerie Pharmaceuticals, Inc, Akorn, Inc, Alcon, Allergan, Aquea Health, Inc, ArcScan, Inc, Bausch & Lomb Incorporated, Beaver-Visitec International, Beyeonics Surgical Ltd, Camras Vision, Inc, Carl Zeiss Meditec, Inc, CorNeat Vision Ltd, Ellex, ELT Sight, Inc, ElutiMed, Equinox, Genentech, Inc, Glaukos Corporation, Injectsense, Inc, IRIDEX Corporation, iSTAR, Ivantis Inc, Johnson & Johnson Vision Care, Inc, Kelotec Inc, LayerBio, Inc, Leica Microsystems, Long Bridge Medical, Inc, MicroOptx, MicroSurgical Technology, Mynosys Cellular Devices Inc, New World Medical, Inc, Ocular Instruments, Ocular Therapeutix, Inc, Omega Ophthalmics, Polyactiva Pty Ltd, Ripple Therapeutics, Sanoculis Ltd, Santen Inc, ScienceBased Health, Sight Sciences, Smartlens, Inc, Strõma Medical Corporation, Thea Pharmaceuticals Limited, Vialase, Inc, Vizzario, and W. L. Gore & Associates, Inc; is on the speakers bureau for Alcon, Allergan, Carl Zeiss Meditec, Inc, Johnson & Johnson Vision Care, Inc, MicroSurgical Technology, and Mundipharma International; and is a contracted researcher for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Camras Vision, Inc, Glaukos Corporation, Ivantis Inc, Johnson & Johnson Vision Care, Inc, New World Medical, Inc, and Santen Inc.
Christophe Baudouin, MD, PhD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Allergan, Horus Pharma, Laboratoires Théa, and Santen Pharmaceutical Co, Ltd; and is a contracted researcher for Horus Pharma, Laboratoires Théa, and Santen Pharmaceutical Co, Ltd.
Preeya K. Gupta, MD, is a consultant for Alcon, Allergan, HanAll Biopharma, Johnson & Johnson Vision Care, Inc, Kala Pharmaceuticals, New World Medical, Inc, Novartis Pharmaceuticals Corporation, Ocular Therapeutix, Inc, Oyster Point Pharma, Inc, ReGenTree, LLC, Sight Sciences, Sun Pharmaceutical Industries, Inc, TearLab Corporation, TissueTech, Inc, and Zeiss.
Nathan M. Radcliffe, MD, is a consultant for Aerie Pharmaceuticals, Inc, Alcon, Alimera Sciences, Allergan, Bausch & Lomb Incorporated, Beaver-Visitec International, Carl Zeiss Meditec, Inc, CATS, Ellex, ELT Sight, Equinox, EyePoint Pharmaceuticals, Glaukos Corporation, IRIDEX Corporation, Ivantis Inc, Kala Pharmaceuticals, Lumenis, New World Medical, Inc, Novartis Pharmaceuticals Corporation, Ocular Science, Ocular Therapeutix, Inc, Omeros Corporation, Quantel SA, Reichert, Inc, Santen Inc, Shire, Sight Sciences, SpyGlass Pharma, Thea Pharmaceuticals Limited, and ViaLase; is on the speakers bureau for Aerie Pharmaceuticals, Inc, Alcon, Alimera Sciences, Allergan, Bausch & Lomb Incorporated, Beaver-Visitec International, CATS, EyePoint Pharmaceuticals, Glaukos Corporation, IRIDEX Corporation, Ivantis Inc, Kala Pharmaceuticals, Lumenis, New World Medical, Inc, Quantel SA, Reichert, Inc, Shire, and Sight Sciences; is a contracted researcher for Allergan and Ocular Therapeutix, Inc; and has ownership interest (future stock options) in CATS, ELT Sight, Equinox, Ivantis Inc, Sight Sciences, SpyGlass Pharma, and ViaLase.
This activity was peer reviewed. The peer reviewer has no relevant financial relationships.
Planners and Managers
MedEdicus planners and managers have no relevant commercial relationships to disclose.
Medical Writer: Tony Realini, MD, is an independent contractor for Aerie Pharmaceuticals, Inc, AsclepiX Therapeutics, Belkin Laser, iSTARMed, Ivantis, Inc, New World Medical, Inc, Nicox, Notal Vision, Ocular Therapeutix, Inc, and Sight Sciences.
MedEdicus LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
MedEdicus LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Commercial Support
This continuing medical education activity is supported through an educational grant from Laboratoires Théa.
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at firstname.lastname@example.org.
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of MedEdicus LLC, Laboratoires Théa, EyeNet, or the American Academy of Ophthalmology.
This CME activity is copyrighted to MedEdicus LLC ©2021. All rights reserved. 249
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation